Critical appraisal of temozolomide formulations in the treatment of primary brain tumors: patient considerations by García, Margarita et al.
© 2009 García et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Cancer Management and Research 2009:1 137–150
Cancer Management and Research
137
R e v i e w
Dovepress
open access to scientific and medical research
Open Access Full Text Article
submit your manuscript | www.dovepress.com
Dovepress 
Critical appraisal of temozolomide formulations 
in the treatment of primary brain tumors: patient 
considerations
Margarita García1 
Ana Clopés2 
Jordi Bruna3 
María Martínez4 
eduard Fort2 
Miguel Gil5
1Clinical Research Unit, institut 
Català d’Oncologia-iDiBeLL, 
L’Hospitalet, Barcelona, Spain; 
2Pharmacy Department, institut 
Català d’Oncologia-iDiBeLL, 
L’Hospitalet, Barcelona, Spain; 
3Neurology Department 
and Neuro-Oncology Unit, Hospital 
Universitario de Bellvitge-iDiBeLL, 
L’Hospitalet, Barcelona, Spain; 
4Oncology Department, Hospital 
del Mar, Barcelona, Spain; 
5Oncology Department and 
Neuro-Oncology Unit, institut Català 
d’Oncologia-iDiBeLL, L’Hospitalet, 
Barcelona, Spain
Correspondence: Margarita García 
Clinical Research Unit, institut Català 
d’Oncologia,   Avinguda Gran via de 
l’Hospitalet, 199-203 08907 L’Hospitalet 
de Llobregat, Barcelona, Spain 
Tel +34 93 260 7331 
Tel +34 93 260 7741 
email mgarciamartin@iconcologia.net
Abstract: Chemotherapy is assuming an increasingly important role in the treatment of 
malignant gliomas, of which temozolomide (TMZ ) is a key part. TMZ belongs to a class of 
second-generation imidazotetrazinone prodrugs that exhibit linear pharmacokinetics and do not 
require hepatic metabolism for activation to the active metabolite. New intravenous (iv) TMZ 
formulations have recently been approved based on studies of bioequivalence between iv and oral 
TMZ. The efficacy of TMZ was initially evaluated in patients with recurrent disease but phase II 
and III trials in newly diagnosed gliomas are available. The results of a large phase III trial 
that compared RT alone vs RT concomitant with oral TMZ created a new standard of adjuvant 
treatment. Efficacy data for iv TMZ on which its approval was based are those extrapolated from 
clinical trials with oral TMZ. No comparative data are available on the differences in tolerability 
and patient satisfaction between oral and iv formulations of TMZ, or for quality of life. New 
oral formulations could encourage the adherence of patients to treatment. Although patients 
presumably would prefer oral treatment, iv formulations may be an alternative in noncompliant 
patients or patients for whom good adherence could not be expected.
Keywords: temozolomide, brain tumors, new formulations, patient considerations, 
chemotherapy, glioblastoma
Current treatment for malignant glioma
Malignant gliomas account for approximately 70% of the 22,500 new cases of 
malignant primary brain tumors that are diagnosed in adults in the United States 
each year.1 The annual incidence of malignant gliomas is approximately 5 to 8 cases 
per 100,000 people. Glioblastomas (GBM) account for approximately 60% to 70% 
of malignant gliomas, anaplastic astrocytomas for 10% to 15%, and anaplastic 
oligodendrogliomas and anaplastic oligoastrocytomas for 10%. Malignant gliomas 
are associated with a high morbidity and mortality. Despite optimal treatment, the 
median survival is only 12 to 15 months for patients with GBM and 2 to 5 years for 
patients with anaplastic gliomas.2
The standard therapy for newly diagnosed malignant gliomas involves surgical 
resection when feasible, radiotherapy (RT), and chemotherapy. Malignant gliomas can-
not be completely eliminated surgically because of their infiltrative nature, but patients 
should undergo maximal surgical resection whenever possible. Surgical debulking 
reduces the symptoms from mass effect and provides tissue for histologic diagnosis 
and molecular studies. The value of surgery in prolonging survival is controversial, but 
patients who undergo extensive resection probably have a modest survival advantage.3 Cancer Management and Research 2009:1 138
García et al Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Radiotherapy is the mainstay of treatment for malignant 
gliomas. The addition of RT to surgery increases survival 
among patients with GBM from a range of 3 to 4 months to a 
range of 7 to 12 months. Conventional RT consists of 60 Gy 
of partial-field external-beam irradiation delivered 5 days per 
week in fractions of 1.8 to 2.0 Gy.4
Chemotherapy is assuming an increasingly important 
role in the treatment of malignant gliomas. Although early 
studies of adjuvant chemotherapy for malignant gliomas 
with the use of nitrosoureas failed to show a benefit, 
2 meta-analyses have suggested that adjuvant nitrosourea-
based chemotherapy results in a modest increase in survival 
(a 6% to 10% increase in the 1-year survival rate).5,6 In 2005, 
the results of a large phase III clinical trial conducted by 
The European Organization for Research and Treatment 
of Cancer (EORTC) and the National Cancer Institute of 
Canada (NCIC) created a new standard of adjuvant treat-
ment.7 This study compared RT alone (60 Gy over a period 
of 6 weeks) with RT and concomitant treatment with oral 
temozolomide (TMZ) 75 mg/m2 of body-surface area per 
day for 6 weeks, followed by adjuvant TMZ therapy (150 to 
200 mg/m2 per day for 5 days every 28 days for 6 cycles), 
in patients with newly diagnosed GBM. The combination 
of RT and TMZ as compared with RT alone, increased the 
median survival (14.6 months vs 12.1 months, P  0.001). 
In addition, the survival rate at 2 years among the patients 
who received RT and TMZ was significantly greater than the 
rate among the patients who received RT alone (26.5% vs 
10.4%). As a consequence, the TMZ regimen was rapidly 
adopted as the new standard of care for patients with newly 
diagnosed GBM who met the inclusion criteria (age younger 
than 70 years and good performance status) of EORTC/ 
NCIC trial.
In general, chemotherapy for recurrent malignant gliomas 
is more effective for anaplastic gliomas than for GBM. The 
efficacy of TMZ was initially demonstrated in patients with 
recurrent disease. Two pivotal phase II studies with identical 
entry criteria were conducted for patients with GBM and with 
anaplastic astrocitoma.8,9 These studies suggested an increase 
in progression-free survival at 6 months (6PFS) compared 
with a historical database (Table 1). On the basis of the 
results of these studies, TMZ 150 to 200 mg/m2 per day for 
5 days every 28 days rapidly became the standard therapy 
for relapsed malignant gliomas in adult patients.
New TMZ formulations have recently been approved by 
the European Medicines Agency (EMEA) and Food and Drug 
Administration (FDA): oral (140 and 180 mg capsules) and 
intravenous (iv) (100 mg vial).10,11
The purpose of this article is to review the evidence 
available about TMZ and its formulations in the treatment 
of primary brain tumors in terms of safety and efficacy, 
and to provide arguments for discussion on the election of 
optimal treatment from the patient’s point of view, with 
consideration of adherence to treatment, quality of life and 
patient preferences.
Pharmacology of temozolomide
Temozolomide belongs to a class of second-generation 
imidazotetrazinone prodrugs that undergo spontaneous 
conversion under physiological conditions to the active 
alkylating agent 5-(3-methyl)1-triazen-1-yl-imidazole-
4-carboxamide (MTIC). Thus, TMZ does not require 
enzymatic demethylation in the liver for activation. This 
fact contributes to its highly reproducible pharmacokinetic 
properties in comparison with other alkylating agents such 
dacarbazine and procarbazine. However this spontaneous 
conversion to MTIC is dependent on pH. The methylation 
of DNA seems to be the principal mechanism responsible 
for the cytotoxicity of TMZ to malignant cells. TMZ is 
spontaneously converted to MTIC, the active metabolite. 
MTIC is degraded to the methyldiazonium cation, which 
transfers the methyl group to DNA, and the final degrada-
tion product, 5-aminoimidazole-4-carboxamide (AIC), 
which is excreted via the kidneys.12 Temozolomide trans-
fers a methyl group to 3 sites: N7-guanine, N3-adenine 
and O6-guanine. The toxic lesion is believed to be the 
O6-guanine adduct, which leads to a lethal cycle of DNA 
mismatch repair if the adduct is not removed by the DNA 
repair protein, O6-alkylguanine-DNA alkyltransferase 
(AGT).13
Phase I studies
The pharmacokinetic and pharmacodynamic properties of 
TMZ in adults have been characterized adequately in 5 phase I 
trials using a daily schedule for 5 days and in 1 phase I trial using 
a daily dose for a continuous 6- or 7-week period and in 2 phase I 
trials conducted on pediatric cancer patients.14–19 Newlands et al 
initially studied iv TMZ at doses of 50 to 200 mg/m2 and it was 
subsequently given orally up to 1200 mg/m2.14 Temozolomide 
exhibited linear pharmacokinetics with increasing dose. Myelo-
toxicity was dose limiting. Temozolomide activity was schedule 
dependent and therefore oral administration was studied as a 
daily for 5 days schedule using total doses between 750 and 
1200 mg/m2  in 42 patients. The recommended dose for phase II 
trials was 150 mg/m2 oral for 5 days for the first course, and if no 
major myelosuppression was detected on day 22 of the 4-week Cancer Management and Research 2009:1 139
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cycle, the subsequent courses could be given at 200 mg/m2 for 
5 days on a 4-week cycle. A subsequent phase I study has been 
conducted to evaluate the plasma pharmacokinetics of TMZ 
administered as an extended continuous oral schedule and to 
compare total plasma exposure over 7 weeks with the conven-
tional 5-day regimen.17 Twenty-four patients with varying tumor 
types (17 of 24 gliomas) received TMZ that was administered 
at 50 mg/m2/day, increasing by 25 mg/m2/day/cohort until at 
100 mg/m2/day grade 4 myelotoxicity forced dose reductions to 
85 mg/m2/day, then to 75 mg/m2/day. At 75 mg/m2/day the regi-
men was extended to 7 weeks, allowing the future potential com-
bination with RT for primary gliomas. Hematological toxicities 
did not exceed grade 2 in 10 patients receiving 75 mg/ m2/day 
TMZ. Peak plasma TMZ concentrations were obtained 30 to 
90 minutes after oral administration. Elimination in plasma was 
best described by a monoexponential equation with an elimina-
tion half-life of 96 ± 16 minutes. No plasma accumulation of 
TMZ occurred. The area under the TMZ plasma vs time curve 
(AUC) was noncumulative between the first and last week of the 
schedule. Temozolomide administration of 75 mg/m2/day over 
a 7-week period permits a 2.1-fold greater drug exposure over 4 
weeks in comparison with the 5-day schedule of 200 mg/m2/day 
repeated every 28 days. Temozolomide (75 mg/m2/day) for 7 
weeks is the recommended starting dose for further assessment 
of this schedule.
Dosage forms
At present there are more than 20 oral antineoplastic 
agents which are being used in cancer care.20 Temo-
zolamide was commercialized in 1999 with several 
dose-presentations: 5 mg, 20 mg, 100 mg and 250 mg. 
Some of them were changed in 2008 in order to make 
the compliance easier by simplifying the oral regimens. 
Two new doses were approved, 140 mg and 180 mg, and 
the 250 mg capsules were withdrawn in Europe. Patients 
treated concomitantly with RT at a dose higher than 
140 mg/day seem to be obviously benefited after avail-
ability of 140 mg tablets, simplifying oral treatment and 
diminishing the probability of toxicity or insufficient 
dosing through a mistake.
Intravenous TMZ obtained EMEA authorization on 
February 17, 2009.10 The approved therapeutic indications 
are the same as the oral ones: “adult patients with newly-
diagnosed GBM concomitantly with RT and subsequently 
as monotherapy treatment and children from the age of 
3 years, adolescents” and “adult patients with malignant 
glioma, such as GBM or anaplastic astrocytoma, showing 
recurrence or progression after standard therapy”. FDA 
approved iv TMZ on February 27, 2009, as 100 mg powder 
for injection.11 The indications and usage provided on label 
information are: “newly diagnosed GBM concomitantly 
with radiotherapy and then as maintenance treatment”, 
also “refractory anaplastic astrocytoma and patients who 
have experienced disease progression on a drug regimen 
containing nitrosourea and procarbazine”. No available data 
of the studies on which the approval is based have been 
published in peer-review journals. As recorded on label 
information, bioequivalence studies have been performed 
and have established that an infusion over 90 minutes 
delivers equivalent TMZ dose and exposure to both TMZ 
and MTIC as does the corresponding TMZ capsules. 
Regarding toxicity, the adverse events newly reported due 
to iv formulation were: pain, irritation, pruritus, warmth, 
swelling and erythema at infusion site, petechiae and hema-
toma. The number of patients in the two studies reported 
on label is 35.
Pharmacokinetics
Pharmacokinetic studies of TMZ have consistently shown 
linear pharmacokinetics with the AUC increasing in 
proportion to the dose. After oral administration to adult 
patients, TMZ is absorbed rapidly with tmax between 0.5 
and 1.5 hours. The good bioavailability (100%) after oral 
administration allows oral administration of the drug. 
After absorption, TMZ was rapidly converted to the active 
substance, MTIC, and subsequently to AIC. Mean tmax 
values for MTIC were 1.5 to 2.0 hours after a single dose, 
and mean tmax of AIC was 2.5 hours. Mean AUC values 
ranged from 14.3 to 15.5 µg/h/mL for a dose of 100 mg/
m2 to 176 µg/h/mL for a dose of 1000 mg/m2. The effect 
of gastric pH and ingestion of food on pharmacokinetic 
properties and oral bioavailability has also been evalu-
ated. Administration of TMZ with food resulted in a 33% 
decrease in Cmax and 9% decrease in AUC.16 Although the 
clinical significance of these changes is unclear, TMZ 
should be administered in the fasting state. Administration 
of TMZ with ranitidine did not result in alterations in the 
extent of absorption of TMZ.21
A phamacokinetic study has been performed comparing 
oral and iv TMZ in 19 patients with primary central nervous 
system malignancies. Intravenous TMZ at 150 mg/m2 over 
90 minutes was bioequivalent to 150 mg/m2 oral TMZ with 
respect to both Cmax and AUC of TMZ and MTIC. The mean 
Cmax and AUC values for TMZ and MTIC were 7.3 µg/mL and 
276 ng/mL, respectively. The same values for oral TMZ were 
7.5 and 282, respectively. The mean AUC values for TMZ and Cancer Management and Research 2009:1 140
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MTIC were 24.6 µg/h/mL and 891 ng/h/mL after iv TMZ and 
23.4 µg/h/mL and 864 ng/h/mL after oral TMZ.10,11
Efficacy studies
Recurrent anaplastic gliomas
Temozolomide was evaluated in a phase II study involving 
patients who had previously been treated with nitrosoureas; 
the study showed a 35% response rate (RR), and 6PFS was 
46% and 5.2 months of median PFS (MPFS).8 A randomized 
phase II trial comparing oral procarbazine with TMZ in recur-
rent GBM showed a 5.4% RR and a 21% 6PFS9. These stud-
ies suggested an increase in 6PFS compared with a historical 
database. The EORTC conducted 2 phase II trials evaluating 
single-agent, standard-schedule TMZ as first- and second-line 
therapy in patients with recurrent or progressive anaplastic 
oligodendroglioma and oligoastrocytoma.22,23 A RR of 53% 
(26% complete responses) and 25% were observed in first- 
and second-line chemotherapy, respectively. Most patients 
that responded to second-line therapy had also responded 
to first-line procarbazine, lomustine, and vincristine (PCV) 
chemotherapy but some patients that do not respond to 
PCV may still respond to TMZ. The NOA-04 phase III, 
multicenter, open-label trial compared the efficacy and 
safety of RT vs chemotherapy (PCV or TMZ) in 318 patients 
with newly diagnosed, supratentorial anaplastic gliomas 
(AG).24 At occurrence of unacceptable toxicity or progressive 
disease (PD), patients in RT arm were treated with one of the 
chemotherapy regimens (1:1 randomization) while patients 
receiving chemotherapy were switched to RT. Median 
time-to-treatment failure (TTF), MPFS, and overall survival 
(OS) did not differ between arms.
At the time of this review the optimal treatment of AG 
is controversial and, while the standard of care in most 
centers is still radiotherapy, in other centers TMZ is rou-
tinely associated with RT in this setting. The results of the 
NOA-4 study suggested that initial therapy in all AG patients 
could be either TMZ or RT alone but ongoing trials are cur-
rently evaluating the role of RT plus concomitant TMZ. In 
addition, patients with an astrocytic tumor (52.6% of cases) 
had a worse TTF than oligoastrocytic (33.2%) or oligoden-
droglioma tumors (14.2%). Oligoastrocytic tumors share 
the same favorable prognosis of pure oligodendroglioma. 
The combination of 1p/19q chromosome deletion and the 
hypermethylation of the MGMT gene promoter bear a large 
risk reduction for TTF and MPFS irrespective of histology 
and treatment.
In conclusion, in this study the presence of an oligo-
dendroglial component in tumors was as strong favorable 
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prognostic factor as combined 1p/19q deletion. MGMT 
promoter methylation was associated with prolonged PFS 
also in the RT arm.
Newly diagnosed GBM
In 2002, Stupp et al reported a pilot trial combining TMZ 
and RT.25 Treatment consisted of surgical debulking to the 
extent feasible or biopsy followed by standard focal RT 
(a total dose of 60 Gy in 30 daily fractions of 2 Gy) with daily 
TMZ (75 mg/m²/day) administered concomitantly during 
the whole period of RT for 49 days at most. After a 4-week 
break, patients received up to 6 cycles of adjuvant oral TMZ 
(150–200 mg/m²) for 5 days every 28 days. Encouraging 
results with a median survival of 16 months (95% CI, 11 to 
21 months) and a 2-year survival rate of 31% (95% CI, 19% 
to 44%) in this phase II trial led to the randomized phase 
III trial by EORTC and NCIC. In 2005, the indications for 
TMZ use were expanded for use in the adjuvant treatment 
of newly diagnosed GBM based on the interim results of 
this randomized phase III trial 7. The final results of this trial 
have recently been published in Lancet Oncology.26 Patients 
were randomized to receive either standard RT (n = 286), 
or standard RT plus concomitant daily TMZ, followed by 
adjuvant TMZ (n = 287) with the same schedule as previous 
phase II study. At the time of this final analysis, 532 (93%) 
had died after a median follow-up of 61 months. Survival 
was significantly greater in the TMZ group than in the RT 
alone group throughout follow-up. Overall survival was 
27.2% at 2 years, 16.0% at 3 years, 12.1% at 4 years, and 
9.8% at 5 years with TMZ, vs 10.9%, 4.4%, 3.0%, and 1.9% 
with RT alone. A benefit of combined therapy was recorded 
in all clinical prognostic subgroups, including patients aged 
60–70 years. Methylation of the O6-methylguanine-DNA 
methyltransferase (MGMT) promoter was the strongest 
predictor for outcome and benefit from TMZ chemotherapy. 
In conclusion, benefits of adjuvant TMZ with RT lasted 
throughout 5 years of follow-up. A few patients in favorable 
prognostic categories survived longer than 5 years and 
MGMT methylation status identifies patients most likely to 
benefit from the addition of TMZ.
A second randomized trial was also published in 2005.27 
It used a dose intensification schedule of TMZ in the adjuvant 
phase involving 150 mg/m2 of TMZ on days 1 to 5 and 15 to 
19. In the concomitant phase TMZ was administered using 
a standard 75 mg/m2. RT was administered to both arms 
at a dose of 60 Gy over 6 weeks. Randomization was ade-
quate but the trial was not blinded and did not include a pla-
cebo. One hundred thirty patients with newly diagnosed GBM 
were randomly assigned (110 assessable patients). Median 
time to progression was 10.8 months in the TMZ group and 
5.2 months in the RT alone group (P = 0.0001). One-year 
PFS rate was 36.6% in the TMZ group and 7.7% in the RT 
alone group. Median OS time was also significantly better 
in TMZ group vs the RT alone group (13.4 vs 7.7 months, 
respectively; P  0.0001), as was the 1-year OS at 56.3% 
vs 15.7% (P  0.0001), respectively.
Efficacy data of iv TMZ which have been approved are 
those extrapolated from clinical trials with oral TMZ.10,11
Different schedules of TMZ 
administration
Even though the only 2 formally approved administration 
regimens are the 5 daily dose schedule and the low-dose daily 
administration regimen in combination with RT, a number 
of other different regimens have been used (Table 1). The 
dose-dense schedules allow a significant increase in the 
dose intensity (over 2-fold TMZ exposure) and deplete 
MGMT, mitigating a potential mechanism of TMZ resis-
tance.28–33 However, improved efficacy of these schedules 
remains to be demonstrated and continuous TMZ exposure 
may induce profound lymphocytopenia. The results of a 
randomized trial that compared PCV regimen vs TMZ (5-day 
or 21-day schedule) for recurrent high-grade glioma have 
been reported.34 A total of 447 patients were randomized 
2:1:1 to PCV, TMZ 200 mg/m2 for 5 days (TMZ-5), and 
TMZ 100 mg/m2 for 21 days (TMZ-21). Both TMZ sched-
ules were repeated every 28 days for up to 9 cycles or until 
progression. Median follow-up was 12 months. Overall sur-
vival for PCV vs TMZ was 6.7 months vs 7.2 months, hazard 
ratio (HR) = 0.91 (0.74–1.11) P = 0.35. Overall survival 
for TMZ-5 vs TMZ-21, HR = 1.32 (0.99, 1.75) P = 0.056. 
Progression-free survival for TMZ-5 vs TMZ-21, HR = 1.38 
(1.04, 1.82) P = 0.023. While TMZ did not show a clear benefit 
over PCV , the comparison of the 2 TMZ schedules demon-
strated that the TMZ-21 regimen was inferior to TMZ-5.
A randomized phase II trial was conducted comparing 
dose-dense 7/14 TMZ and metronomic TMZ in 51 patients 
with newly diagnosed GBM following surgery and concur-
rent TMZ and RT. The OS was 11.2 months in patients 
receiving the metronomic schedule and the median sur-
vival was not reached for the dose-dense TMZ schedule. 
Median PFS was 3.8 months for the metronomic group and 
6.8 months for the dose-dense group. Although these results 
are preliminary, early analysis indicates that the dose-dense 
TMZ regimen may be better than metronomic TMZ.35 So 
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support the use of alternative TMZ regimen outside specific 
protocols and clinical investigation.
Temozolomide rechallenge in recurrent 
malignant glioma
Temozolomide is well tolerated and may have activity despite 
prior TMZ exposure. Perry et al reviewed their experience 
with a continuous TMZ schedule (50 mg/m2 daily), given 
at progression after conventional 5-day TMZ. Patients 
were reported in 3 groups:36 Group 1, included 21 patients 
with GBM after progression on conventional TMZ; 
Group 2, included 14 patients with GBM at first recurrence 
after completion of standard concomitant and adjuvant TMZ; 
and Group 3, included 14 patients with other AG at second 
relapse on conventional TMZ. In Group 1, the 6PFS was 
17%. In Group 2, with a median disease-free interval after 
adjuvant TMZ of 3 months (range 2–10) the 6PFS was 57%. 
In Group 3, 6PFS was 42%. Toxicity was mild and lympho-
cytopenia was common but no serious opportunistic infections 
were identified. Despite their retrospective condition, these 
results demonstrate that administration of TMZ as rechallenge 
is an active regimen if there is an interval 2 months after 
adjuvant prior TMZ therapy. Nevertheless, some of these 
cases could represent a pseudoprogression phenomenon. 
Wick et al have conducted another retrospective review of 
80 patients with 90 recurrent glioma rechallenged with TMZ.37 
Some patients experiencing PD during TMZ therapy were 
rechallenged with alternative TMZ regimens. Other group of 
patients was rechallenged after stable disease in a TMZ-free 
interval and they were evaluated separately. The 6PFS was 
48% in patients with anaplastic gliomas (12/25) and 27.7% 
in those with GBM (14/47). The 6PFS for patients switched 
during TMZ were 16.7 and 26.3% in the anaplastic glioma 
and GBM groups respectively and 57.9% and 28.6% in the 
same groups when only patients rechallenged after a TMZ-
free interval of at least 8 weeks were considered. Relevant 
hematological toxicity (NCI-CTC grade 3–5) was observed in 
22 of 90 rechallenged patients, and relevant nonhematological 
toxicity in 10 of 90 patients of the same group.
Low-grade glioma
Low-grade glioma may respond to chemotherapy. Response 
rates of over 40% to 60% to TMZ chemotherapy have been 
reported in 2 reports of patients treated for progressive 
low-grade glioma.38,39 However, inclusion in these trials 
was based on initial histology, and the presence of contrast 
enhancement in 60% to 70% of the patients and the con-
firmed transformation into anaplastic glioma in over 50% 
of the operated patients clearly indicates that most patients 
had a higher-grade tumor and that the observed RRs are in 
accordance with earlier reports. There are 2 reports of TMZ 
administration (standard schedule) to patients with previ-
ously untreated low-grade glioma.40,41 Objective RRs were 
10% and 17%, respectively, with a 14% to 48% rate of minor 
responses or clinical improvement. These results suggest that 
TMZ does have activity for lower-grade glioma. However, 
whether there is an advantage in treating these patients with 
upfront chemotherapy for 12 months or longer compared 
with initial RT is currently the subject of a randomized 
EORTC/NCIC trial.
Neoadjuvant setting
High RRs with first-line TMZ chemotherapy immediately 
after surgery or biopsy and before RT have been reported. 
Gilbert et al reported on 36 GBM patients receiving 
standard-dose TMZ for up to 4 cycles.42 An overall RR of 
42% with a MPFS of 4 months and OS of 13 months were 
observed. A phase II study with neoadjuvant combination 
chemotherapy of TMZ plus cisplatin on 40 newly diagnosed 
GBM showed a RR of 45% (95% CI, 27%–58%) and OS 
of 12.5 months.43 Overall survival is comparable with the 
standard sequence of TMZ and RT followed by TMZ. 
One phase II trial evaluated the administration of TMZ in 
32 elderly patients with a median age of 75 years.40 The RR 
was 31% (95% CI, 14%–48%) and the OS was 6.2 months, 
comparable with the 5.2 to 5.6 months recently reported 
for RT alone.44 A randomized trial by the Nordic Neuro-
Oncology Group comparing RT with a standard dose of 
TMZ is ongoing.
Combination with other agents
TMZ in combination with other alkylating agents (eg, 
BCNU), has been tested and schedule-dependent toxicity is 
to be expected due to fact that repair of the DNA damage 
induced by both agents depends on MGMT. Phase II trials 
of TMZ in combination with other agents are summarized in 
Table 2.45–47 At the time of this review, no combination has 
demonstrated superiority to monotherapy in phase III setting. 
Studies are under way to evaluate the combination of TMZ 
with biotherapy agents in the treatment of malignant glioma 
such as metalloproteinase inhibitor marimastat, thalidomide 
and cis-retinoic acid. All have showed modest evidence 
of activity in patients with recurrent GBM.48–50 A phase II 
trial showed the safety and feasibility of the adjunction of 
cilengitide to the standard regimen of TMZ and concomitant 
RT, followed by TMZ maintenance.51 Overall survival was Cancer Management and Research 2009:1 144
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promising, notably in the patients with a methylated MGMT 
gene promoter. Recently a worldwide randomized phase III 
trial has been launched. Patients with a methylated gene 
promoter are eligible for randomization between standard 
TMZ/RT + TMZ, vs the same standard regimen enhanced 
by the addition of cilengitide.
Recently a phase II trial of bevacizumab (10 mg/kg 
every 2 weeks) in combination with TMZ (75 mg/m2/day) 
and RT in 70 patients with newly diagnosed GBM has 
been presented.52 After completion of RT patients are then 
placed on a maintenance phase of bevacizumab (10 mg/kg 
every 2 weeks) and TMZ (150–200 mg/m2/day 5 days out 
of every 28) until progression or 24 months. There were 
grade 3–4 hematological and nonhematological toxicity 
(Table 2). Median progression free survival was 13 months 
and OS was 25 months. Despite a good theoretical rationale 
for all regimens, the available data from these phase II 
trials do not allow for any firm conclusions with regard to 
increased activity. A phase III study starts now to answer 
this question.
Safety and tolerability
In phase I, the dose-limiting toxicity of the drug was thrombo-
cytopenia. Grade 3–4 thrombocytopenia occurred in 10% of 
the 138 patients in a phase II study of TMZ at 200 mg/m2/day 
for 5 days every 28 days for chemonaïve GBM patients and 
150 mg/m2/day for 5 days every 28 days for pre-treated 
patients, which was allowed to escalate to 200 mg/m2 if no 
grade 3 or 4 toxicity was observed in first cycle, with 7% 
of leukopenia and 4.5% of neutropenia.53 Nonhematologic 
toxicity was observed only in 8% of patients, with grade 3–4 
nausea and vomiting without prior antiemesis medication. 
When studied in combination with cranial RT, TMZ at 
75 mg/m2/day 7 days a week concomitant with 60 Gy of 
RT, grade 3–4 neutropenia occurred in 4 patients (6%), 
and grade 3–4 thrombocytopenia in another 4. Forty-nine 
patients (79%) experienced grade 3–4 lymphocytopenia.25 
In this study, 3 patients who were receiving corticosteroids 
and presented grade 3–4 neutropenia and lymphocytopenia 
needed hospitalization and treatment interruption and 2 of 
these developed Pneumocystis carinii pneumonia. The same 
study explored adjuvant TMZ at 200 mg/m2/day for 5 days 
every 28 days for 6 cycles. Grade 3–4 neutropenia or throm-
bocytopenia occurred in 2% and 6% of cycles, respectively. 
Nonhematologic toxicities were rash and moderate to severe 
fatigue during concomitant treatment in 2 patients at grade 
3 and in 1 patient in adjuvant setting. Interestingly, on MRI, 
signs of leukoencephalopathy without clinical symptoms 
were observed among the 14 patients that were alive longer 
than 18 months. One of these patients showed intracranial 
hypertension, refractory seizures and loss of vision 33 months 
after beginning RT. Another patient showed memory loss 
and hemiplegia 17 months after beginning RT.
In the less selected phase III setting, patients were 
randomized to receive RT alone vs RT concomitant with 
TMZ followed by 6 cycles of adjuvant TMZ. Four percent 
of patients in the concomitant arm (12/287) experienced 
grade 3–4 neutropenia and 3% (9/287) grade 3–4 thrombo-
cytopenia. Fourteen percent of patients presented any type 
of grade 3–4 hematological toxicity, 4% presented grade 3–4 
neutropenia and 11% presented grade 3–4 thrombocytopenia 
during adjuvant TMZ treatment.7 Severe infections were 
observed in 9 patients of the TMZ plus RT arm (3%) but 
6 patients treated only with RT (2%) presented severe 
infections, too. Thirty-three percent of patients in the 
combination arm experienced grade 3–4 fatigue, and 26% 
in the control arm. There were 28 thromboembolic events, 
16 in RT group and 12 in the combination group. Two 
patients presented opportunistic pneumonia, one in each arm. 
Another two patients died because of cerebral hemorrhage 
without coagulation alteration or thrombocytopenia, both in 
the combination arm. No late toxicity was observed with a 
median follow-up of 28 months. The dosing regimens tested 
in order to prolong the exposition to TMZ in compressed and 
extended dosing schedules summarized in Table 1 showed 
induction of profound lymphocytopenia and severe second-
ary infections.
However no opportunistic infection was reported, possi-
bly due to P . carinii pneumonia prophylaxis administered to 
patients if they were found to have grade 3 or more lympho-
cytopenia, as was done in one of the studies mentioned.31
Mechanisms of resistance
The mechanisms of resistance to TMZ evaluated in pre-
clinical studies are the enzyme AGT, the deficiency in 
the mismatch repair pathway and the base excision repair 
pathway. Of these mechanisms, AGT plays a primary role in 
resistance to TMZ and other alkylating agents by removing 
the alkyl groups from the O6 position of guanine, in effect 
reversing the cytotoxic lesion of TMZ. Several preclinical 
studies have examined methods for reducing the resistance 
to alkylating agents such as TMZ. O6-benzylguanine and 
lomeguatrib are potent inhibitors of AGT-mediated resis-
tance to DNA. Preclinical studies suggest a role for these 
agents in increasing the therapeutic index of TMZ, and 
phase I trials have been reported.54–57 Another possible Cancer Management and Research 2009:1 145
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mechanism of resistance to TMZ is the base excision repair 
pathway. Studies have shown that treatment of human 
tumor cells with TMZ induced an increase in the activity of 
poly (ADP-ribose) polymerase (PARP), and the inhibition 
of PARP has been reported to enhance the cytotoxicity of 
methylating agents.58 A phase I trial evaluated the safety and 
pharmacokinetic–pharmacodynamic profile of AGO14699, 
a PARP inhibitor, in combination with TMZ.59
MGMT and resistance 
to temozolomide in gliomas
MGMT gene on chromosome band 10q26 encodes a ubiqui-
tous DNA repair enzyme, present in normal human tissues. 
This enzyme, MGMT, removes and accepts alkyl groups 
from the O6 position of methylguanine without affecting 
DNA integrity. This is called a suicide enzyme because by 
doing that, MGMT inactivates itself irreversibly. MGMT 
plays a key role in reverting lethal DNA damage induced by 
TMZ, and thus neutralizing the cytotoxic effect. Furthermore, 
preclinical studies have shown that in the absence of this 
enzyme, cells are more susceptible to TMZ. High levels of 
MGMT in the tumor are associated with resistance to TMZ 
and other alkylating agents. Different methods have been 
described to measure MGMT levels in tumors. The protein 
can be detected by immunohistochemistry (IHC), and also the 
enzyme activity can be measured by high-performance liquid 
chromatography (HPLC). Promoter methylation status can 
be assessed by different methods. A retrospective study has 
been recently published analyzing the role of IHC as a clinical 
biomarker. The authors do not recommend the use of anti-
MGMT immunohistochemistry as a routine biomarker for 
diagnostic purposes because of observer variability and lack of 
association with the MGMT promoter methylation status and 
survival.60 A methylation-specific polymerase chain reaction 
assay (MSP-PCR) shows high sensitivity and specificity. This 
method requires a small amount of DNA and can be extracted 
from paraffin-embedded tissue or from cryopreserved tissue 
samples.61 The presence of a methylated MGMT allele is only 
due to tumor cells. Until future validation, this test cannot 
yet be considered for routine clinical decision. Other assays 
are now under evaluation, such as MGMT hypermethylation 
analysis using methylation-specific multiplex ligation-
dependent probe amplification (MS-MLPA).62 The potential 
value of MGMT hypermethylation evaluation by MS-MLPA 
was recently shown in a small group of patients with a GBM 
treated with TMZ. Nevertheless, further evaluation is needed 
to establish its clinical value. Epigenetic silencing of MGMT 
by promoter hypermethylation is present in approximately 
40% of primary GBM and represents the main mechanism 
to reduce MGMT expression and diminish the DNA repair 
activity. Moreover, it has been shown to be an independent 
predictor of response to alkylating chemotherapy in patients 
with newly diagnosed GBM treated with RT and concomitant 
TMZ and adjuvant TMZ.63 In this study TMZ only benefited 
patients with a methylated MGMT gene promoter. TMZ 
treated patients with a nonsilenced MGMT gene had an OS 
and PFS similar to patients who initially received radiotherapy 
alone. These results can give the impression that patients 
without MGMT promoter methylation should not be treated 
with alkylating chemotherapy. However, these patients 
had at least a minor benefit from TMZ and other alterna-
tive strategies are currently not available outside clinical 
trials.64,65 Nevertheless it is important to note that this analysis 
was performed retrospectively, and therefore these results 
require prospective validation. The accrual of a trial by RTOG 
and EORTC (RTOG 0525/EORTC 26052-22053) is actually 
closed. In this study patients with newly diagnosed GBM are 
stratified by MGMT methylation status before randomization 
to a TMZ schedule (standard daily dose for 5/28 days or a 
21/28 days dose-dense regimen). Data from this study are 
expected at the end of 2009.
Health-related quality of life in 
patients treated with temozolomide
An important goal to evaluate the usefulness of any treatment in 
cancer is the ability to maintain or improve the patient’s quality 
of life. The tools used to determine how the general quality 
of life is affected by cancer are the health-related quality of 
life (HRQOL) self-report questionnaires. The most used tests 
are the Quality of Life Core-30 (QLQ-C30) and the Func-
tional Assessment of Cancer Therapy-General (FACT-G) 
questionnaires, both supplemented with modules designed to 
specifically assess symptoms due to brain cancer (QLQ-BN20 
and FACT-Br).66–69 These instruments are well validated and 
have robust psychometric properties as a result of rigorous 
testing and development in several international cancer clinical 
trials. These questionnaires measure quality of life status in a 
multidimensional way, providing several scales of symptoms 
and functional domains of patient’s life. The effect of TMZ 
treatment over quality of life has been well assessed in patients 
with high grade gliomas, mainly GBM, and more recently in 
patients with low grade gliomas.
The randomized trial of RT alone vs RT with concomitant 
and adjuvant TMZ conducted by EORTC-NCIC was also 
focused on the evaluation of quality of life.7,70 In this study, 
at baseline HRQOL scores were the same for both groups. Cancer Management and Research 2009:1 147
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During subsequent assessments, groups did not differ sig-
nificantly for any of the 7 preselected scales analyzed. The 
addition of performance status and type of surgery data to 
the analysis did not change the results. This trial allows us 
to conclude that adding concomitant and adjuvant TMZ to 
RT does not adversely affect HRQOL, although the sample 
calculation was not based on detecting changes in HRQOL. 
Two phase II studies had been performed to evaluate the 
efficacy of TMZ after GBM recurrence where HRQOL was 
also considered as a secondary end point.7–9 Joint results 
of HRQOL for these two works were reported in a sepa-
rate publication.71,72 This work showed that before disease 
progression, patients treated with TMZ had an improvement 
in most of preselected HRQOL domains analyzed compared 
with their pretreatment scores. Conversely, patients treated 
with procarbazine reported deterioration in HRQOL that was 
independent of whether or not the disease had progressed. 
Baseline scores between the two treatment arms were similar. 
Patients with disease progression, independent of treatment, 
experienced a decline in HRQOL domains assessed. Only 
1 study has been carried out to determine whether TMZ 
treatment affects quality of life of patients with recurrent 
anaplastic astrocytomas and anaplastic oligoastrocytomas.72 
This study showed that scores in seven preselected domains 
were maintained or improved in patients who did not have 
disease progression and a gradual decrease in scores as pro-
gression neared and worse than baseline scores at time of 
progression. The results of an interim analysis about HRQOL 
in a phase II trial in newly diagnosed low grade gliomas have 
been recently reported.73 Patients treated in this study showed 
either no significant changes or improvement in HRQOL 
scores at each cycle of TMZ compared to their own baseline 
scores. However, despite the good overall compliance rate 
of questionnaires (71%–85%), patients who progressed and 
those who had intolerable side effects that needed cessation 
of therapy were not included in the analysis.
A small phase II trial that was performed in progressive 
low grade gliomas to assess benefits of TMZ in recurrent 
low-grade gliomas showed that an improvement of HRQOL 
scores in 1 or more items was more frequent in patients with 
radiological response to treatment than in patients with stable 
or progressive disease.39
In summary, the schedule and adverse effects of TMZ do 
not deteriorate the patients’ quality of life in newly diagnosed 
or recurrent glioblastomas (level I evidence). The main factor 
implied in the decrease HRQOL scores in these patients is 
tumour progression. In high grade gliomas, TMZ seems to 
present the same effect in quality of life, although we have 
less studies available (level II evidence). Currently, there 
is little available evidence of TMZ in low-grade gliomas, 
although the preliminary results are encouraging. The main 
criticisms in the quality of life studies available are: in the 
design of studies the sample calculation is based on OS and 
not on HRQOL scores and each study selects some arbi-
trary scales to analyze and none make any comment about 
cognitive or language status of patients and their ability to 
understand the questionnaires. Moreover, we should not 
forget that the analyzed group of patients corresponds to a 
trial-selected population that could not reflect the tolerance 
to this treatment in general population.
Adherence and patient preferences
It has been generally believed that cancer patients were always 
compliant to treatment. But nowadays, the number of oral 
compounds is increasing in oncology and some studies have 
showed that adherence must be focused and followed. To 
our knowledge, little information is published in oncology 
on the incidence of nonadherence, which ranges from 25% to 
98%.74 Nonadherence can have multiple consequences such as 
inducing the physician to attribute progression of the disease 
to a lack of activity of the drug, and increasing the consump-
tion of healthcare resources.75 In a recent study, the factors 
associated with poor adherence in 169 patients with chronic 
myeloid leukemia who were treated with imatinib were: 
demographic variables such as age, living alone and being 
male; treatment variables such as duration of treatment and 
different combinations for a dose; and the patient–physician 
relationship.76 The same risk factors have been published in 
the recommendations of the Spanish AIDS groups, including 
adverse events secondary to treatment.77 When feasible, on-
site pharmacies and consultations with a pharmacist should be 
encouraged because they may facilitate adherence.78
There are no published studies about adherence to TMZ, 
but adherence of patients treated with this drug could be com-
promised by several factors, such as consequences of tumor 
resection and the complexity of treatment regimen. In any 
case, these data would be relevant to eventually choosing the 
better treatment for any individual patient, as iv formulations 
are available if predictors of poor adherence are present.
Liu et al studied the advanced cancer patient’s preferences 
between oral and parenteral treatment.79 Of 103 assessable 
patients, 92 preferred oral chemotherapy, 10 preferred iv 
chemotherapy, and 1 had no preference. Patient preferences 
were not associated with age, sex, site of primary cancer, 
or previous chemotherapy experiences. Major reasons for 
preferring oral chemotherapy were convenience, problems Cancer Management and Research 2009:1 148
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with iv access or needles, and a better environment for 
medication (taking medication at home). Studies comparing 
clinical efficacy and safety of oral and parenteral forms of 
the same drug are not common. Data are available for colon, 
breast and lung cancer patients.80–83 To date, all but one of the 
studies based on patient surveys have showed a preference 
for oral over parenteral treatments and there is little question 
that oral regimens are more convenient for patients, as long 
as efficacy is guaranteed.
After assuming that oral and iv formulations of TMZ 
are bioequivalent in terms of pharmacokinetics, toxicity and 
efficacy, the question raised is about their advantages and dis-
advantages. Oral chemotherapy offers advantages for patient 
convenience in terms of flexibility of timing and location of 
administration, which can lead to potential reductions in the 
use of healthcare resources. There are few concerns about the 
bioavailability of oral TMZ used during fasting. As the oral 
administration of chemotherapy results in prolonged drug 
exposure, the scientific community has explored extended 
schemes in order to enlarge the time of drug exposure and 
avoid resistance to TMZ. First comparative results are now 
available. This approach does not appear to show any advan-
tage for iv formulations. From the patient’s point of view, there 
are neither comparative available data on the differences of 
tolerability and patient satisfaction between oral and iv for-
mulations of TMZ, nor quality of life data. One of potential 
problems arising from oral administration of chemotherapy is 
the lack of treatment compliance. Data on compliance are lim-
ited and there is no study with TMZ, but interestingly the main 
clinical importance of iv formulations could be the treatment 
of noncompliant patients or patients for whom good adherence 
could not be expected, such as children or adolescents.
Conclusions
The best treatment available for GBM includes surgery if 
possible, RT and chemotherapy with TMZ. Toxicity of TMZ, 
which particularly consists of myelotoxicity, is manage-
able. Alternative TMZ regimens are being tested, especially 
extended ones, in which profound lymphocytopenia has 
been observed and severe opportunistic infections should 
be prevented, but they are not recommended outside clini-
cal trials. In spite of a robust biological rationale, MGMT 
testing is not yet incorporated in routine clinical practice due 
to lack of definitive validation. Oral TMZ formulations are 
well established and new oral formulations can encourage 
the adherence of patients to treatment. Intravenous formu-
lations may be an alternative if needed, although patients 
presumably would prefer oral treatment. For patients, TMZ 
treatment is beneficial, tolerable, preserves quality of life 
and is easy to administer.
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